Endocrine Related Cancer · 2018 · 27 citations · 51 references
MedicineOncologyPharmacologyCancer PharmacologyCell SignalingSignal TransductionCancer ProgressionDrug ResistanceMtor Inhibitor TherapyPancreatic CancerTherapeutic ResistanceAnticancer Drug ResistanceCdk1 InactivationKinase Inhibitor ResistanceMtorc1 SignalingResistance To Cell Cycle-targeted DrugsReversal Of Drug ResistanceTherapeutic Resistance MechanismsTumor Resistance
Pancreatic neuroendocrine tumors (panNETs) are often inoperable at diagnosis. The mTORC1 inhibitor everolimus has been approved for the treatment of advanced NETs. However, the regular development of resistance to everolimus limits its clinical efficacy. We established two independent everolimus-resistant panNET (BON1) cell lines (BON1 RR1, BON1 RR2) to find potential mechanisms of resistance. After 24 weeks of permanent exposure to 10 nM everolimus, BON1 RR1 and BON1 RR2 showed stable resistance with cellular survival rates of 96.70% (IC 50 = 5200 nM) and 92.30% (IC 50 = 2500 nM), respectively. The control cell line showed sensitivity to 10 nM everolimus with cellular survival declining to 54.70% (IC 50 = 34 nM). Both resistant cell lines did not regain sensitivity over time and showed persistent stable resistance after a drug holiday of 13 weeks. The mechanisms of resistance in our cell line model included morphological adaptations, G1 cell cycle arrest associated with reduced CDK1(cdc2) expression and decreased autophagy. Cellular migration potential was increased and indirectly linked to c-Met activation. GSK3 was over-activated in association with reduced baseline IRS-1 protein levels. Specific GSK3 inhibition strongly decreased BON1 RR1/RR2 cell survival. The combination of everolimus with the PI3Kα inhibitor BYL719 re-established everolimus sensitivity through GSK3 inhibition and restoration of autophagy. We suggest that GSK3 over-activation combined with decreased baseline IRS-1 protein levels and decreased autophagy may be a crucial feature of everolimus resistance, and hence, a possible therapeutic target.
51
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
Kathryn O’Reilly, F. Rojo, Qing‐Bai She et al. · Cancer Research · 2006 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +16
Targeting PI3K/Akt/mTOR Signaling in Cancer
Camillo Porta, Chiara Paglino, Alessandra Mosca · Frontiers in Oncology · 2014 · 1.5K citations · Full text
Medicine, Oncology, Pharmacology +15